Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GLSI with free AI briefings, catalyst countdowns, and dilution alerts.

GLSI · Greenwich LifeSciences, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$5.9M Cash on Hand
7.2mo Cash Runway
20.6% Short Interest
$57 Analyst Target (2)
Follow GLSI by email Get an email when GLSI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GLSI, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
HER2/neu Peptide Vaccine GLSI-100 Breast Cancer Phase 3 · NCT05232916 Recruiting

Also used in these trials (approved or third-party drugs, not GLSI's own candidates): Carboplatin, Cetuximab, Paclitaxel.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GLSI holds $5.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.5M/quarter from operations, an estimated runway of 7.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 70 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GLSI files for a raise →

👥 Who Owns GLSI

Insiders 40% Institutions (93 holders) 12.2% Public and other holders 47.8%
HolderTypeShares% of sharesAs of
Snehal Patel
CEO and CFO, Director, 10% owner · +4.59M options
Insider 5,611,402 38.23% 2026-07-28
Blackrock Inc. Institution (13F) 511,991 3.49% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 288,610 1.97% 2026-09-30
Jaye Thompson
VP Clinical Reg Affairs · +299,636 options
Insider 264,148 1.80% 2024-11-21
Geode Capital Management, LLC Institution (13F) 187,239 1.28% 2026-09-30
State Street Corporation Institution (13F) 159,448 1.09% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 92,885 0.63% 2026-09-30
Northern Trust Corporation Institution (13F) 82,754 0.56% 2026-09-30
Goldman Sachs Group Inc Institution (13F) 56,793 0.39% 2026-09-30
Vanguard Fiduciary Trust Co Institution (13F) 53,226 0.36% 2026-09-30
Bank Of New York Mellon Corporation Institution (13F) 48,999 0.33% 2026-09-30
STRS Ohio Institution (13F) 34,700 0.24% 2026-09-30

Share count 14,678,208 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-07-29
filed 2026-07-30
Patel Snehal
Purchase (P) 700 $13.10 5,611,402
2026-07-28
filed 2026-07-30
Patel Snehal
Purchase (P) 1,500 $13.59 5,610,702
2026-07-27
filed 2026-07-29
Patel Snehal
Purchase (P) 1,500 $13.62 5,609,202
2026-07-24
filed 2026-07-27
Patel Snehal
Purchase (P) 1,100 $12.88 5,607,702
2026-07-23
filed 2026-07-27
Patel Snehal
Purchase (P) 2,500 $13.14 5,606,602

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full GLSI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GLSI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.